KRAS and colorectal carcinoma: Additionally, the cause of resistance to cetuximab (an anti-EGFR antibody) in CRC cells with mutant KRAS was due to an accumulation of methylglyoxal (MGO)—a byproduct of glycolysis—and activation of the AKT enzyme [48].